List of Excipients in Branded Drug MARCAINE WITH EPINEPHRINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Henry Schein Inc	MARCAINE WITH EPINEPHRINE	bupivacaine hydrochloride and epinephrine bitartrate	0404-9908	ASCORBIC ACID
Henry Schein Inc	MARCAINE WITH EPINEPHRINE	bupivacaine hydrochloride and epinephrine bitartrate	0404-9908	EDETATE CALCIUM DISODIUM
Henry Schein Inc	MARCAINE WITH EPINEPHRINE	bupivacaine hydrochloride and epinephrine bitartrate	0404-9908	HYDROCHLORIC ACID
Henry Schein Inc	MARCAINE WITH EPINEPHRINE	bupivacaine hydrochloride and epinephrine bitartrate	0404-9908	MONOTHIOGLYCEROL
Henry Schein Inc	MARCAINE WITH EPINEPHRINE	bupivacaine hydrochloride and epinephrine bitartrate	0404-9908	SODIUM CHLORIDE

Marcaine With Epinephrine Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Marcaine with epinephrine is an injectable combination of bupivacaine hydrochloride and epinephrine used for local and regional anesthesia. Its commercial position is driven less by molecule exclusivity than by injectable quality, preservative selection, container compatibility, supply reliability, and workflow advantages. The core formulation is mature and exposed to generic competition, but opportunities remain in preservative-free presentations, ready-to-use packaging, longer stability, lower waste, and differentiated regional-anesthesia delivery systems.

What is the formulation of Marcaine with epinephrine?

Marcaine with epinephrine is supplied as sterile injectable bupivacaine hydrochloride with epinephrine at a concentration of 1:200,000. The principal strengths are 0.25% and 0.5% bupivacaine hydrochloride.

Formulation attribute	Commercial description
Active anesthetic	Bupivacaine hydrochloride
Vasoconstrictor	Epinephrine 1:200,000
Bupivacaine strengths	0.25% and 0.5%
Dosage form	Sterile injectable solution
Route	Local infiltration, peripheral nerve block, sympathetic nerve block, and caudal or epidural use where labeled
pH	Typically acidic, approximately 3.5 to 5.5
Primary excipient functions	Tonicity, pH control, solvent system, antioxidant protection
Manufacturer associated with brand	Pfizer through Hospira, depending on product and market
Regulatory status	FDA-approved prescription injectable product

The formulation is designed around two stability problems. Bupivacaine hydrochloride requires an aqueous acidic environment for solubility and chemical stability. Epinephrine is more vulnerable to oxidation and pH-related degradation, requiring tight control of oxygen exposure, light, container closure, and antioxidant protection.

Which excipients are used in Marcaine with epinephrine?

The principal excipients and formulation aids are sodium chloride, water for injection, pH-adjusting agents, and a sulfite antioxidant system. Exact inactive-ingredient declarations can vary by presentation and package configuration.

Sodium chloride

Sodium chloride adjusts osmolality toward a physiologically acceptable range. It also helps maintain injection comfort and limits the need for higher concentrations of other tonicity agents.

Water for injection

Water for injection is the vehicle. Injectable water quality, bacterial endotoxin control, particulate control, and container closure integrity are central to product approval.

pH adjustment

Hydrochloric acid or sodium hydroxide may be used to establish the target pH. The pH must balance several competing requirements:

• Bupivacaine solubility
• Epinephrine stability
• Injection tolerability
• Compatibility with the container closure
• Control of degradation products

Sodium metabisulfite or related sulfite protection

Epinephrine-containing local anesthetic products commonly use a sulfite antioxidant, such as sodium metabisulfite, to reduce oxidative degradation. Sulfite sensitivity is a labeled safety issue. A product strategy that removes sulfite must demonstrate equivalent epinephrine stability through alternative controls, such as oxygen reduction, improved container closure, nitrogen headspace, light protection, or another qualified antioxidant.

The excipient profile is therefore not a minor formulation detail. It directly affects labeling, stability, patient selection, packaging, manufacturing cost, and differentiation from standard generic bupivacaine with epinephrine.

What excipient strategies could differentiate Marcaine with epinephrine?

The strongest opportunities are incremental reformulations that solve recognized hospital and ambulatory-surgery problems without changing the pharmacologic active ingredients.

Preservative-free formulation

A preservative-free presentation could target neuraxial and regional-anesthesia settings where clinicians prefer to minimize unnecessary antimicrobial preservatives. The commercial product would need to distinguish between:

• Preservative-free status
• Sulfite-free status
• Single-dose packaging
• Compatibility with neuraxial administration

These are different claims. Removing methylparaben, where present in a multidose presentation, does not necessarily remove sulfite used to stabilize epinephrine. A sulfite-free product would require a separate stability and safety justification.

A preservative-free, single-dose product has the clearest hospital value proposition because it can reduce preservative exposure and simplify pharmacy policies. The tradeoff is higher packaging cost and a shorter period after opening.

Sulfite-free epinephrine formulation

Sulfite-free positioning could address patients with documented sulfite sensitivity and institutions seeking to reduce excipient-related alerts. The technical challenge is significant because epinephrine oxidation can produce discoloration and potency loss.

Potential controls include:

• Low-oxygen manufacturing and filling
• Nitrogen or inert-gas headspace
• High-barrier glass or polymer containers
• Enhanced light protection
• Oxygen-scavenging closure systems
• Alternative antioxidant systems
• Tighter dissolved-oxygen specifications

Any alternative antioxidant would require toxicological assessment, extractables and leachables testing, compatibility work, and FDA review. A sulfite-free product could support a premium price, but the target market is narrower than the general bupivacaine market.

Ready-to-use syringes

Prefilled syringes could reduce preparation steps, medication-selection errors, and operating-room waste. The commercial opportunity is strongest in:

• Emergency departments
• Ambulatory surgery centers
• Dental and oral-surgery practices
• Labor and delivery units
• Regional-anesthesia carts
• Hospital pharmacies with high sterile-compounding workloads

The main development barriers are syringe-material compatibility, adsorption, extractables, plunger performance, terminal sterilization or aseptic processing, and shelf-life validation. A prefilled syringe would also need clear differentiation from standard vials because its value is operational rather than pharmacological.

Low-waste packaging

Small-volume, single-dose vials and ampules can reduce discarded residual drug. A manufacturer could offer package sizes aligned with common block volumes, although excessive concentration or volume segmentation can increase inventory complexity.

Packaging optimization should consider:

• Typical dose ranges
• Residual volume
• Number of doses per procedure
• Controlled-substance and medication-management workflows
• Bar-code scanning
• Automated dispensing cabinet compatibility
• Breakage risk for glass ampules

Longer in-use stability

Longer in-use stability could support pharmacy batching and procedural workflows, but the claim must be tightly defined. It may refer to stability:

• In the unopened container
• After vial puncture
• After transfer into a syringe
• In an elastomeric pump
• After admixture with another local anesthetic
• Under refrigerated or room-temperature conditions

The highest-value claim is usually demonstrated stability in the actual delivery device used by hospitals, such as a syringe or infusion reservoir. Such claims may support a new drug application supplement or a 505(b)(2) development pathway, depending on the degree of change and regulatory strategy.

What formulations are protected by patents?

The original bupivacaine and epinephrine formulation is an old injectable product with no meaningful remaining composition-of-matter exclusivity. Generic bupivacaine hydrochloride with epinephrine products compete directly on the active ingredients and basic dosage form.

As of June 2024, the FDA Orange Book did not provide a commercially significant active patent barrier comparable to a modern branded specialty drug for the established Marcaine with epinephrine injection. The key commercial protection is therefore likely to come from formulation improvements, device integration, manufacturing know-how, trademarks, and hospital contracts rather than legacy product patents.

Potential patentable subject matter includes:

• Sulfite-free epinephrine stabilization
• Specific antioxidant combinations
• Low-oxygen filling processes
• Container closure systems
• Prefilled syringe configurations
• Extended stability in a delivery device
• Local-anesthetic admixture stability
• Controlled-release or liposomal bupivacaine systems
• Novel concentration or dose-volume combinations
• Digital identification and medication-safety packaging

A patent strategy based only on substituting one conventional tonicity agent for another would usually be weak. Stronger protection would require unexpected stability, reduced degradation, improved tolerability, or a meaningful manufacturing or device advantage.

When does Marcaine with epinephrine lose exclusivity?

Marcaine with epinephrine has already lost practical market exclusivity. Bupivacaine hydrochloride with epinephrine is available from multiple generic manufacturers, and the product is not dependent on a current new chemical entity exclusivity period.

Exclusivity category	Status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the established product
Pediatric exclusivity	No current commercially relevant period identified
New formulation exclusivity	No broad active period identified for the base product
Orange Book patent barrier	No significant active barrier identified as of June 2024
Generic competition	Established

The competitive question is not whether generic entry is possible. It has already occurred. The relevant question is whether a differentiated formulation can obtain its own regulatory and commercial position.

What is the Orange Book status of Marcaine with epinephrine?

The FDA Orange Book lists approved drug products and, where applicable, patents and exclusivity information. Marcaine with epinephrine is an old approved injectable product. Its Orange Book position does not create the type of patent-linked generic entry delay associated with newer branded products.

A generic applicant may rely on an abbreviated new drug application for the same active ingredients, dosage form, route, strength, and labeling framework, subject to FDA requirements. A materially different excipient profile, packaging system, delivery device, or stability claim can require a separate regulatory analysis.

Are there Paragraph IV challenges involving Marcaine with epinephrine?

Paragraph IV litigation is not a central current risk for the base Marcaine with epinephrine product because the principal exclusivity and patent periods have expired. Generic manufacturers have no obvious reason to challenge a commercially meaningful unexpired patent estate protecting the legacy formulation.

Paragraph IV risk could become relevant if a new branded product obtains patents covering:

• A sulfite-free formulation
• A new container closure
• A ready-to-use syringe
• A proprietary delivery device
• A specific stability profile
• A controlled-release bupivacaine formulation

In that scenario, the relevant dispute would concern the new formulation or device patents, not the historical Marcaine formulation.

What FDA regulatory pathway applies to an improved excipient formulation?

The regulatory pathway depends on the extent of the change.

Product concept	Likely regulatory route
Same active ingredients and conventional injection with minor excipient variation	ANDA or supplemental pathway, depending on reference-product relationship
New excipient system with clinical or safety differentiation	505(b)(2) NDA may be appropriate
New delivery device or prefilled presentation	NDA, supplement, or combination-product review
Liposomal or controlled-release bupivacaine	505(b)(2) or full NDA, depending on formulation and evidence
Same product manufactured at a new site	CMC supplement or application amendment

A new excipient may trigger studies for local tolerance, systemic exposure, impurities, extractables and leachables, sterility assurance, container closure integrity, and compatibility with administration devices.

A label claim such as "sulfite-free" or "preservative-free" would need precise definition and supporting manufacturing controls. The claim cannot be inferred solely from the absence of methylparaben.

How strong is the patent estate for a new Marcaine excipient strategy?

The patent estate for the legacy product is weak because the product is mature and genericized. A new excipient strategy can be stronger, but only when the claims cover a technically specific and commercially necessary solution.

Strategy	Patent strength	Regulatory difficulty	Commercial potential
Conventional sodium chloride adjustment	Low	Low	Low
Preservative-free single-dose vial	Low to moderate	Moderate	Moderate
Sulfite-free epinephrine stabilization	Moderate to strong	High	Moderate to high
Prefilled syringe	Moderate	Moderate to high	High
Extended stability in pump or syringe	Moderate	High	High in institutional settings
New antioxidant composition	Moderate	High	Moderate
Liposomal or controlled-release bupivacaine	Stronger potential	High	High, but competitive
Manufacturing process with reduced oxidation	Moderate	High	Moderate

The most defensible strategy would combine composition claims, container claims, process claims, and use claims. A single narrow formulation claim would be vulnerable to design-around through a different antioxidant, oxygen-control method, or container material.

Which companies are challenging the Marcaine market?

The competitive field includes generic injectable manufacturers and branded local-anesthetic suppliers. Relevant competitors may include products marketed by Pfizer/Hospira, Fresenius Kabi, Hikma, Sagent Pharmaceuticals, Eugia, and other approved generic manufacturers, depending on the specific strength, presentation, and market.

Competition is based on:

• Contract price
• Supply continuity
• Shortage performance
• Available vial sizes
• Preservative-free options
• Bar-code and packaging compliance
• Hospital formulary status
• Wholesaler availability
• Product quality history

A new entrant with a differentiated excipient strategy would compete against low-cost generic vials and must create measurable workflow or safety value. Clinical equivalence alone is unlikely to justify a substantial premium.

What licensing and commercial opportunities exist?

No major current licensing transaction is required to commercialize a differentiated Marcaine with epinephrine formulation. The most practical opportunities are partnership-based:

Hospital and ambulatory-surgery contracts

A supplier could sell a preservative-free or ready-to-use product through group purchasing organizations and direct institutional contracts. Supply assurance and reduced preparation labor may be more persuasive than a narrow excipient claim.

Device partnerships

Syringe manufacturers, elastomeric-pump suppliers, and regional-anesthesia device companies could provide access to validated delivery systems. The strongest partnership model would integrate the drug, container, labeling, and administration device.

Contract manufacturing

A specialized sterile injectable manufacturer could provide aseptic filling, nitrogen overlay, low-oxygen processing, and high-barrier packaging. These capabilities are important for epinephrine stability.

Co-development of controlled-release products

A controlled-release bupivacaine product would compete in a different segment from conventional Marcaine with epinephrine. Its value would depend on duration of analgesia, opioid-sparing evidence, procedure-specific outcomes, and reimbursement.

What revenue exposure does the product have?

Public company filings generally do not isolate revenue for Marcaine with epinephrine as a standalone SKU. The product is part of broader injectable anesthesia and hospital-product portfolios. Revenue exposure is therefore tied to portfolio share, pricing, tender wins, manufacturing continuity, and generic substitution rather than patent protection.

A conventional generic formulation has limited pricing power. A premium product could support better economics if it demonstrates one or more of the following:

• Lower preparation labor
• Lower medication waste
• Fewer medication-selection errors
• Better epinephrine shelf stability
• Reduced sulfite exposure
• Improved compatibility with pumps or syringes
• Reliable supply during injectable shortages

What manufacturing and IP barriers matter most?

The primary barriers are operational rather than molecular. They include:

• Sterile manufacturing capacity
• Epinephrine oxidation control
• Low dissolved oxygen
• Container closure integrity
• Glass or polymer compatibility
• Sulfite and impurity control
• Sterility and endotoxin compliance
• Stability after device transfer
• Global packaging and serialization requirements

Manufacturing know-how may be more difficult to replicate than the basic formulation. A company that controls validated low-oxygen filling, high-barrier packaging, and long-term stability data could maintain a practical advantage even with limited patent breadth.

Key Takeaways

• Marcaine with epinephrine is a mature bupivacaine hydrochloride and epinephrine injectable with no meaningful remaining base-product exclusivity.
• The central excipient issues are tonicity, acidic pH, epinephrine oxidation, sulfite exposure, and container compatibility.
• Preservative-free, sulfite-free, prefilled, and low-waste presentations offer the clearest commercial opportunities.
• The strongest differentiation is likely to come from packaging, delivery devices, stability, and workflow economics.
• A 505(b)(2) strategy may be appropriate for a materially differentiated excipient or delivery system.
• Legacy Orange Book patents do not appear to create a significant current barrier to generic competition.
• Manufacturing controls and institutional supply contracts may provide greater commercial value than narrow composition patents.
• A new product must demonstrate measurable hospital value because conventional generic bupivacaine with epinephrine is widely available.

FAQs About Marcaine With Epinephrine Excipient Strategy

Is Marcaine with epinephrine preservative-free?

The answer depends on the specific presentation. Single-dose and multidose products can have different inactive ingredients. The approved package insert and container label control for each marketed configuration.

Does Marcaine with epinephrine contain sulfites?

Epinephrine-containing local anesthetic formulations commonly contain a sulfite antioxidant to limit epinephrine oxidation. The exact sulfite and concentration should be verified against the applicable product labeling.

Can a sulfite-free bupivacaine product obtain patent protection?

Yes. Protection could cover a specific antioxidant-free formulation, oxygen-control process, container closure, or stability profile. Patent strength would depend on technical specificity and unexpected stability results.

Would a prefilled Marcaine syringe require new FDA approval?

A prefilled syringe can require a new regulatory submission or supplement because the container, closure, device, sterility process, stability profile, and labeling may differ from the vial product.

Is there a commercial premium for preservative-free bupivacaine with epinephrine?

A premium is possible in hospitals and ambulatory centers if the product reduces preparation labor, waste, preservative exposure, or medication-use risk. Price acceptance depends on documented workflow and supply benefits.

References

1. DailyMed. (2024). Marcaine and Marcaine with epinephrine: Bupivacaine hydrochloride injection prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

5. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. https://www.fda.gov/drugs/types-applications/505b2-application